Ann: Appendix 3Y for Eric Rose, page-45

If GG keeps buying then a takeover offer may be on the cards, at which time I wonder who else would come out of the woodwork.
Excerpt from the link -

Merck, for instance, made a splash in October when it paid $4 billion up front—plus $18 billion in potential milestones—to get its hands on 3 ADCs from Daiichi Sankyo.

As for AbbVie’s purchase of ImmunoGen, a securities filing at the end of the year detailed how the company didn’t actually pursue the biotech until other potential suitors were already at the negotiating table.

Two other companies, identified only as “Party A” and “Party B,” were exploring a possible purchase of ImmunoGen before the biotech’s board identified AbbVie and a group of other companies as potential bidders. After ImmunoGen solicited offers from all of the companies, AbbVie’s final proposal won out.

https://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023